|
1
|
Ojesina AI, Lichtenstein L, Freeman SS,
Pedamallu CS, Imaz-Rosshandler I, Pugh TJ, Cherniack AD, Ambrogio
L, Cibulskis K, Bertelsen B, et al: Landscape of genomic
alterations in cervical carcinomas. Nature. 506:371–375. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Fruman DA and Rommel C: PI3K and cancer:
Lessons, challenges and opportunities. Nat Rev Drug Discov.
13:140–156. 2014. View
Article : Google Scholar : PubMed/NCBI
|
|
3
|
Liu P, Cheng H, Roberts TM and Zhao JJ:
Targeting the phosphoinositide 3-kinase pathway in cancer. Nat Rev
Drug Discov. 8:627–644. 2009. View
Article : Google Scholar : PubMed/NCBI
|
|
4
|
Cancer Genome Atlas Research Network:
Albert Einstein College of Medicine; Analytical Biological
Services; Barretos Cancer Hospital; Baylor College of Medicine;
Beckman Research Institute of City of Hope; Buck Institute for
Research on Aging; Canada's Michael Smith Genome Sciences Centre;
Harvard Medical Schoo; Helen F. Graham Cancer Center & Research
Institute at Christiana Care Health Services et al, . Integrated
genomic and molecular characterization of cervical cancer. Nature.
543:378–384. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Rodon J, Dienstmann R, Serra V and
Tabernero J: Development of PI3K inhibitors: Lessons learned from
early clinical trials. Nat Rev Clin Oncol. 10:143–153. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Okkenhaug K, Graupera M and Vanhaesebroeck
B: Targeting PI3K in cancer: impact on tumor cells, their
protective stroma, angiogenesis, and immunotherapy. Cancer Discov.
6:1090–1105. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Thorpe LM, Yuzugullu H and Zhao JJ: PI3K
in cancer: Divergent roles of isoforms, modes of activation and
therapeutic targeting. Nat Rev Cancer. 15:7–24. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Furet P, Guagnano V, Fairhurst RA,
Imbach-Weese P, Bruce I, Knapp M, Fritsch C, Blasco F, Blanz J,
Aichholz R, et al: Discovery of NVP-BYL719 a potent and selective
phosphatidylinositol-3 kinase alpha inhibitor selected for clinical
evaluation. Bioorg Med Chem Lett. 23:3741–3748. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Juric D, Rodon J, Tabernero J, Janku F,
Burris HA, Schellens JHM, Middleton MR, Berlin J, Schuler M,
Gil-Martin M, et al: Phosphatidylinositol 3-Kinase α-selective
inhibition with alpelisib (BYL719) in PIK3CA-altered solid tumors:
Results from the first-in-human study. J Clin Oncol. 36:1291–1299.
2018. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Mayer IA, Abramson VG, Formisano L, Balko
JM, Estrada MV, Sanders ME, Juric D, Solit D, Berger MF, Won HH, et
al: A Phase Ib study of alpelisib (BYL719), a PI3Kα-specific
inhibitor, with letrozole in ER+/HER2-metastatic breast cancer.
Clin Cancer Res. 23:26–34. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Kaufman B, Shapira-Frommer R, Schmutzler
RK, Audeh MW, Friedlander M, Balmaña J, Mitchell G, Fried G,
Stemmer SM, Hubert A, et al: Olaparib monotherapy in patients with
advanced cancer and a germline BRCA1/2 mutation. J Clin Oncol.
33:244–250. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Scott CL, Swisher EM and Kaufmann SH:
Poly(ADP-ribose) polymerase inhibitors: Recent advances and future
development. J Clin Oncol. 33:1397–1406. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Balasubramaniam S, Beaver JA, Horton S,
Fernandes LL, Tang S, Horne HN, Liu J, Liu C, Schrieber SJ, Yu J,
et al: FDA approval summary: Rucaparib for the treatment of
patients with deleterious BRCA mutation-associated advanced ovarian
cancer. Clin Cancer Res. 23:7165–7170. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Kim G, Ison G, McKee AE, Zhang H, Tang S,
Gwise T, Sridhara R, Lee E, Tzou A, Philip R, et al: FDA approval
summary: Olaparib monotherapy in patients with deleterious germline
BRCA-mutated advanced ovarian cancer treated with three or more
lines of chemotherapy. Clin Cancer Res. 21:4257–4261. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Scott LJ: Niraparib: First global
approval. Drugs. 77:1029–1034. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Murai J, Huang SY, Das BB, Renaud A, Zhang
Y, Doroshow JH, Ji J, Takeda S and Pommier Y: Trapping of PARP1 and
PARP2 by clinical PARP inhibitors. Cancer Res. 72:5588–5599. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Murai J, Huang SY, Renaud A, Zhang Y, Ji
J, Takeda S, Morris J, Teicher B, Doroshow JH and Pommier Y:
Stereospecific PARP trapping by BMN 673 and comparison with
olaparib and rucaparib. Mol Cancer Ther. 13:433–443. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Shen Y, Rehman FL, Feng Y, Boshuizen J,
Bajrami I, Elliott R, Wang B, Lord CJ, Post LE and Ashworth A: BMN
673, a novel and highly potent PARP1/2 inhibitor for the treatment
of human cancers with DNA repair deficiency. Clin Cancer Res.
19:5003–5015. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Shen Y, Aoyagi-Scharber M and Wang B:
Trapping Poly (ADP-Ribose) polymerase. J Pharmacol Exp Ther.
353:446–457. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Pommier Y, O'Connor MJ and de Bono J:
Laying a trap to kill cancer cells: PARP inhibitors and their
mechanisms of action. Sci Transl Med. 8:362ps172016. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Thaker PH, Salani R, Brady WE, Lankes HA,
Cohn DE, Mutch DG, Mannel RS, Bell-McGuinn KM, Di Silvestro PA,
Jelovac D, et al: A phase I trial of paclitaxel, cisplatin, and
veliparib in the treatment of persistent or recurrent carcinoma of
the cervix: An NRG oncology study (NCT#01281852). Ann Oncol.
28:505–511. 2017.PubMed/NCBI
|
|
22
|
Prasad CB, Prasad SB, Yadav SS, Pandey LK,
Singh S, Pradhan S and Narayan G: Olaparib modulates DNA repair
efficiency, sensitizes cervical cancer cells to cisplatin and
exhibits anti-metastatic property. Sci Rep. 7:128762017. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Wang D, Li C, Zhang Y, Wang M, Jiang N,
Xiang L, Li T, Roberts TM, Zhao JJ, Cheng H and Liu P: Combined
inhibition of PI3K and PARP is effective in the treatment of
ovarian cancer cells with wild-type PIK3CA genes. Gynecol Oncol.
142:548–556. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Lee GY, Kenny PA, Lee EH and Bissell MJ:
Three-dimensional culture models of normal and malignant breast
epithelial cells. Nat Methods. 4:359–365. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Bian X, Gao J, Luo F, Rui C, Zheng T, Wang
D, Wang Y, Roberts TM, Liu P, Zhao JJ and Cheng H: PTEN deficiency
sensitizes endometrioid endometrial cancer to compound PARP-PI3K
inhibition but not PARP inhibition as monotherapy. Oncogene.
37:341–351. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Shepherd JH: Cervical cancer. Best Pract
Res Clin Obstet Gynaecol. 26:293–309. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Kastan MB and Bartek J: Cell-cycle
checkpoints and cancer. Nature. 432:316–323. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Wang D, Wang M, Jiang N, Zhang Y, Bian X,
Wang X, Roberts TM, Zhao JJ, Liu P and Cheng H: Effective use of
PI3K inhibitor BKM120 and PARP inhibitor Olaparib to treat PIK3CA
mutant ovarian cancer. Oncotarget. 7:13153–13166. 2016.PubMed/NCBI
|
|
29
|
Ibrahim YH, Garcia-Garcia C, Serra V, He
L, Torres-Lockhart K, Prat A, Anton P, Cozar P, Guzmán M, Grueso J,
et al: PI3K inhibition impairs BRCA1/2 expression and sensitizes
BRCA-proficient triple-negative breast cancer to PARP inhibition.
Cancer Discov. 2:1036–1047. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
van Gent DC, Hoeijmakers JH and Kanaar R:
Chromosomal stability and the DNA double-stranded break connection.
Nat Rev Genet. 2:196–206. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Fong PC, Boss DS, Yap TA, Tutt A, Wu P,
Mergui-Roelvink M, Mortimer P, Swaisland H, Lau A, O'Connor MJ, et
al: Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA
mutation carriers. N Engl J Med. 361:123–134. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
McCabe N, Turner NC, Lord CJ, Kluzek K,
Bialkowska A, Swift S, Giavara S, O'Connor MJ, Tutt AN, Zdzienicka
MZ, et al: Deficiency in the repair of DNA damage by homologous
recombination and sensitivity to poly(ADP-ribose) polymerase
inhibition. Cancer Res. 66:8109–8115. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Konstantinopoulos PA, Ceccaldi R, Shapiro
GI and D'Andrea AD: Homologous recombination deficiency: Exploiting
the fundamental vulnerability of ovarian cancer. Cancer Discov.
5:1137–1154. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Cardillo TM, Sharkey RM, Rossi DL, Arrojo
R, Mostafa AA and Goldenberg DM: Synthetic lethality exploitation
by an anti-trop-2-SN-38 antibody-drug conjugate, IMMU-132, plus
PARP inhibitors in BRCA1/2-wild-type triple-negative breast cancer.
Clin Cancer Res. 23:3405–3415. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Johnson N, Li YC, Walton ZE, Cheng KA, Li
D, Rodig SJ, Moreau LA, Unitt C, Bronson RT, Thomas HD, et al:
Compromised CDK1 activity sensitizes BRCA-proficient cancers to
PARP inhibition. Nat Med. 17:875–882. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Mo W, Liu Q, Lin CC, Dai H, Peng Y, Liang
Y, Peng G, Meric-Bernstam F, Mills GB, Li K and Lin SY: mTOR
inhibitors suppress homologous recombination repair and synergize
with PARP inhibitors via regulating SUV39H1 in BRCA-proficient
triple-negative breast cancer. Clin Cancer Res. 22:1699–1712. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
37
|
González-Billalabeitia E, Seitzer N, Song
SJ, Song MS, Patnaik A, Liu XS, Epping MT, Papa A, Hobbs RM, Chen
M, et al: Vulnerabilities of PTEN-TP53-deficient prostate cancers
to compound PARP-PI3K inhibition. Cancer Discov. 4:896–904. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Cardnell RJ, Feng Y, Mukherjee S, Diao L,
Tong P, Stewart CA, Masrorpour F, Fan Y, Nilsson M, Shen Y, et al:
Activation of the PI3K/mTOR pathway following PARP inhibition in
small cell lung cancer. PLoS One. 11:e01525842016. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Philip CA, Laskov I, Beauchamp MC, Marques
M, Amin O, Bitharas J, Kessous R, Kogan L, Baloch T, Gotlieb WH and
Yasmeen A: Inhibition of PI3K-AKT-mTOR pathway sensitizes
endometrial cancer cell lines to PARP inhibitors. BMC Cancer.
17:6382017. View Article : Google Scholar : PubMed/NCBI
|
